Vaccine one of the vaccine components is more robust than the others and suppresses the growth and immune response to the other components. This phenomenon was first noted in the trivalent Sabin polio vaccine, where the amount of serotype 2 virus in the vaccine had to be reduced to stop it from interfering with the "take" of the serotype 1 and 3 viruses in the vaccine. This phenomenon has also been found to be a problem with the dengue vaccines currently being researched, where the DEN-3 serotype was found to predominate and suppress the response to DEN-1, −2 and −4 serotypes.
Sabin Vaccine Institute Africa, and the Americas. Sabin is currently working on multiple vaccines for humans including vaccines for Hookworm infection ("Na"-GST-1, "Na"-APR-1), Schistosomiasis ("Sm"-TSP-2), Chagas disease ("Tc"24, TSA-1), Leishmaniasis ("Ld"-NH36, PdSP15), Severe acute respiratory syndrome (SARS)/Middle East respiratory syndrome (MERS) (Pan-β-CoVax), Soil-transmitted helminthiasis (STH), and Onchocerciasis (Ov-"103", Ov-"RAL-2"). In 2006, Sabin co-founded the Global Network for Neglected Tropical Diseases in order "to raise the awareness, political will and funding necessary to control and eliminate the most common NTDs." Through its work on NTDs, Sabin hopes to reduce poverty caused by these diseases as many of them have been shown to adversely affect